FDA accepts NDA for mometasone furoate/formoterol fumarate combination for maintenance treatment of asthma
Schering-Plough announced that a New Drug Application (NDA) for a fixed-dose combination of mometasone furoate and formoterol fumarate has been filed and accepted for review by the FDA for the maintenance treatment of asthma in patients ≥12 years of age.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.